# US 10,307,387 B1 · D-serine treatment for neurological disorders that cause seizures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,387 B1
- Document ID: US10307387B1
- Status: Granted
- Kind: B1
- Application number: 15/834,804
- Filed: 2017-12-07
- Granted: 2019-06-04
- Earliest claimed: 2013-02-21
- Assignees: The Florida State University Research Foundation, Inc.
- Applicants: Florida State University Research Foundation, Inc.
- Inventors: Sanjay Kumar
- Web page: https://patentgrep.com/patent/US10307387B1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.

## Claims

### Claim 1

A method of treating epilepsy comprising artificially administering a composition comprising D-serine to an epileptic patient in an amount effective to inhibit the occurrence of epileptic seizures by selectively contacting a region of the patient's brain with the composition, the region being pre-identified as having cells expressing GluN3 subunit-containing triheteromeric NMDARs.

### Claim 2 (depends on 1)

The method of claim 1, wherein the occurrence of epileptic seizures is inhibited by preventing excitotoxic cell loss in the region of the patient's brain that is selectively contacted.

### Claim 3 (depends on 1)

The method of claim 1, wherein the region of the patient's brain that is selectively contacted is the patient's temporal lobe.

### Claim 4 (depends on 1)

The method of claim 1, wherein the region of the patient's brain that is selectively contacted is a medial entorhinal cortex of the patient's temporal lobe.

### Claim 5 (depends on 1)

The method of claim 1, wherein the D-serine is artificially administered by injecting a temporal lobe of the patient's brain with the composition, thereby selectively contacting the temporal lobe.

### Claim 6 (depends on 1)

The method of claim 1, wherein the D-serine is artificially administered by injecting a medial entorhinal cortex of the patient's temporal lobe with the composition, thereby selectively contacting the medial entorhinal cortex.

### Claim 7 (depends on 1)

The method of claim 1, wherein the epileptic seizures are caused by temporal lobe epilepsy.

### Claim 8 (depends on 1)

The method of claim 1, wherein inhibiting the occurrence of epileptic seizures includes reducing the frequency of chronic epileptic seizures.

### Claim 9

A method of treating a neurological disorder that causes seizures, the method comprising artificially administering a seizure-reducing effective amount of a composition comprising D-serine to a patient in need thereof by selectively contacting a region of the patient's brain with the composition, the region being pre-identified as having cells expressing GluN3 subunit-containing triheteromeric NMDARs.

### Claim 10 (depends on 9)

The method of claim 9, wherein the region of the patient's brain that is selectively contacted is the patient's temporal lobe.

### Claim 11 (depends on 9)

The method of claim 9, wherein the region of the patient's brain that is selectively contacted is a medial entorhinal cortex of the patient's temporal lobe.

### Claim 12 (depends on 9)

The method of claim 9, wherein D-serine is artificially administered by injecting a temporal lobe of the patient's brain with the composition, thereby selectively contacting the temporal lobe.

### Claim 13 (depends on 9)

The method of claim 9, wherein D-serine is artificially administered by injecting a medial entorhinal cortex of the patient's temporal lobe with the composition.

### Claim 14 (depends on 9)

The method of claim 9, wherein the seizures are caused by temporal lobe epilepsy, thereby selectively contacting the medial entorhinal cortex.

### Claim 15 (depends on 9)

The method of claim 9, wherein treating the seizures reduces the frequency of and/or substantially eliminates chronic epileptic seizures.

### Claim 16 (depends on 9)

The method of claim 9, wherein the seizure reducing effective amount of D-serine prevents excitotoxic cell loss.